Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Unknown 2Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 4Hodgkin Disease 3Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Recurrence 2Neoplasms 2Advanced Breast Cancer 2Neoplasm Metastasis 1NSCLC 1Metastatic HER2-positive Breast Cancer 1Lung Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2-negative Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Vinorelbine × Clear all
NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡